Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice

Arthritis and Rheumatology

Volumn 68, Issue 11, 2016, Pages 2728-2739

  Oaks, Zachary ^a   Winans, Thomas ^a   Caza, Tiffany ^a   Fernandez, David ^a   Liu, Yuxin ^a   Landas, Steve K ^a   Banki, Katalin ^a   Perl, Andras ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; DYNAMIN RELATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NADH UBIQUINONE OXIDOREDUCTASE CORE SUBUNIT S3; OXYGEN; PHOSPHOLIPID ANTIBODY; PROTEIN; PROTEIN KINASE B; RAPAMYCIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); S6 KINASE; SOLVENT; SUCCINATE DEHYDROGENASE (UBIQUINONE); TRANSALDOLASE; UNCLASSIFIED DRUG; BETA2 GLYCOPROTEIN 1; DNM1L PROTEIN, MOUSE; DYNAMIN; IMMUNOSUPPRESSIVE AGENT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIENZYME COMPLEX; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DISORDERS OF METAL METABOLISM; DRUG MECHANISM; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMEOSTASIS; LIVER MITOCHONDRION; LUPUS ERYTHEMATOSUS NEPHRITIS; MITOCHONDRIAL DYSFUNCTION; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY CHAIN; SYSTEMIC LUPUS ERYTHEMATOSUS; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; OXIDATIVE STRESS; OXYGEN CONSUMPTION;

ANIMALS; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODY FORMATION; BETA 2-GLYCOPROTEIN I; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DYNAMINS; ELECTRON TRANSPORT CHAIN COMPLEX PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICE, KNOCKOUT; MITOCHONDRIA, LIVER; MULTIPROTEIN COMPLEXES; OXIDATIVE STRESS; OXYGEN CONSUMPTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSALDOLASE;

EID: 84992623337     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39791     Document Type: Article

References (49)

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011;365:2110–21.
2. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T-cell activation–induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2983–8.
3. Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, et al. Activation of mammalian target of rapamycin controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009;182:2063–73.
4. Lai ZW, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R, et al. Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol 2013;191:2236–46.
5. Caza TN, Fernandez D, Talaber G, Oaks Z, Haas M, Madaio MP, et al. HRES-1/RAB4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. Ann Rheum Dis 2014;73:1888–97.
6. Perl A. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol 2013;9:674–86.
7. Sarbassov DD, Sabatini DM. Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem 2005;280:39505–9.
8. 2-glycoprotein I. Arthritis Rheum 2011;63:2774–82.
9. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120–4.
10. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677–86.
11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.
12. Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003;349:1177–9.
13. Canaud G, Bienaime F, Tabarin F, Bataillon G, Seilhean D, Noel LH, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med 2014;371:303–12.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
15. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
16. Liu Y, Yu J, Oaks Z, Marchena-Mendez I, Francis L, Bonilla E, et al. Liver injury correlates with biomarkers of autoimmunity and disease activity and represents an organ system involvement in patients with systemic lupus erythematosus. Clin Immunol 2015;160:319–27.
17. Asherson RA, Cervera R, Piette JC, Font J, Lie JT, Burcoglu A, et al. Catastrophic antiphospholipid syndrome: clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998;77:195–207.
18. Ambrosino P, Lupoli R, Spadarella G, Tarantino P, di Minno A, Tarantino L, et al. Autoimmune liver diseases and antiphospholipid antibodies positivity: a meta-analysis of literature studies. J Gastrointestin Liver Dis 2015;24:25–34.
19. Hanczko R, Fernandez D, Doherty E, Qian Y, Vas G, Niland B, et al. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest 2009;119:1546–57.
20. Peng SL. Experimental use of murine lupus models. In: Perl A, editor. Methods in molecular medicine: autoimmunity methods and protocols. 1st ed. Totowa (NJ): Humana; 2005. p. 227–72.
21. Perl A, Hanczko R, Doherty E. Assessment of mitochondrial dysfunction in lymphocytes of patients with systemic lupus erythematosus. In: Perl A, editor. Methods in molecular medicine: autoimmunity methods and protocols. 2nd ed. Clifton (NJ): Springer; 2012. p. 61–89.
22. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J 2011;435:297–312.
23. 2 glycoprotein I and cardiolipin: species specificity and charge-dependent binding. J Immunol 1996;156:2631–41.
24. Perl A, Hanczko R, Lai ZW, Oaks Z, Kelly R, Borsuk R, et al. Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. Metabolomics 2015;11:1157–74.
25. Desai BN, Myers BR, Schreiber SL. FKBP12-rapamycin-associated protein associates with mitochondria and senses osmotic stress via mitochondrial dysfunction. Proc Natl Acad Sci U S A 2002;99:4319–24.
26. Perl A. Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol 2016;12:169–82.
27. Kashatus JA, Nascimento A, Myers LJ, Sher A, Byrne FL, Hoehn KL, et al. Erk2 phosphorylation of Drp1 promotes mitochondrial fission and MAPK-driven tumor growth. Mol Cell 2015;57:537–51.
28. Chang CR, Blackstone C. Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J Biol Chem 2007;282:21583–7.
29. Bernatsky S, Boivin JF, Joseph L, Rajan R, Zoma A, Manzi S, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52:1481–90.
30. Park SM, Rajapaksha T, Zhang M, Sattar H, Fichera A, Ashton-Rickardt P, et al. CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. Apoptosis 2008;13:41–51.
31. Vance JE. MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. Biochim Biophys Acta 2014;1841:595–609.
32. + autophagosomes and the accumulation of mitochondria during autophagy. PLoS One 2014;9:e84392.
33. Miwa S, Jow H, Baty K, Johnson A, Czapiewski R, Saretzki G, et al. Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice. Nat Commun 2014;5:3837.
34. Tarr T, Muzes G, Pitlik E, Lakos G, Csepany T, Soltesz P, et al. Is the primary antiphospholipid syndrome a forerunner of SLE? Orv Hetil 2005;146:203–7. In Hungarian.
35. McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, Rubertone MV, et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 2004;50:1226–32.
36. Perl A, Hanczko R, Telarico T, Oaks Z, Landas S. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med 2011;17:395–403.
37. Nagy G, Ward J, Mosser DD, Koncz A, Gergely P Jr, Stancato C, et al. Regulation of CD4 expression via recycling by HRES-1/RAB4 controls susceptibility to HIV infection. J Biol Chem 2006;281:34574–91.
38. Pullmann R Jr, Bonilla E, Phillips PE, Middleton FA, Perl A. Haplotypes of the HRES-1 endogenous retrovirus are associated with development and disease manifestations of systemic lupus erythematosus. Arthritis Rheum 2008;58:532–40.
39. Serasinghe MN, Weider SY, Renault TT, Elkholi R, Asciolla JJ, Yao JL, et al. Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell 2015;57:521–36.
40. Roberts MS, Woods AJ, Shaw PE, Norman JC. ERK1 associates with αvβ3 integrin and regulates cell spreading on vitronectin. J Biol Chem 2003;278:1975–85.
41. Li Y, Gorelik G, Strickland FM, Richardson BC. Oxidative stress, T cell DNA methylation, and lupus. Arthritis Rheumatol 2014;66:1574–82.
42. Gergely PJ Jr, Grossman C, Niland B, Puskas F, Neupane H, Allam F, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:175–90.
43. Quinlan CL, Orr AL, Perevoshchikova IV, Treberg JR, Ackrell BA, Brand MD. Mitochondrial complex II can generate reactive oxygen species at high rates in both the forward and reverse reactions. J Biol Chem 2012;287:27255–64.
44. Benard G, Bellance N, James D, Parrone P, Fernandez H, Letellier T, et al. Mitochondrial bioenergetics and structural network organization. J Cell Sci 2007;120:838–48.
45. Kato H, Perl A. Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol 2014;192:4134–44.
46. Lambert M, Boullier A, Hachulla E, Fruchart JC, Teissier E, Hatron PY, et al. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 2000;9:299–300.
47. 2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002;46:2686–94.
48. Finn RS. Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer 2012;1:247–56.
49. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460:392–5.